The 14 references in paper N. Novikova A., A. Shilova S., Н. Новикова А., А. Шилова С. (2017) “ОСОБЕННОСТИ НАЗНАЧЕНИЯ ТРОЙНОЙ АНТИТРОМБОТИЧЕСКОЙ ТЕРАПИИ С ПРИМЕНЕНИЕМ РИВАРОКСАБАНА У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ, ПЕРЕНЕСШИХ СТЕНТИРОВАНИЕ КОРОНАРНЫХ АРТЕРИЙ // THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING” / spz:neicon:aterotromboz:y:2017:i:1:p:114-121

1
Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis,2007, 18: 193-9.
(check this in PDF content)
2
Husted S, De Caterina R, Andreott Huber Storey WeitzJI Esc Working Group On Thrombosis Task Force On Anticoagulants In Heart Disease OBNon-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel.Thromb Haemost, 2014, 111: 781-782.
(check this in PDF content)
3
Wang TY, Robinson LA, Ou FS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J, 2008, 155: 361-8.
(check this in PDF content)
4
ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet,2006, 367: 1903-12.
(check this in PDF content)
5
Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace,2010, 12: 1360420.
(check this in PDF content)
6
Popma CJ, Sheng S, Korjian S, et al. Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: results from the TRACER angiographic substudy. Circ Cardiovasc Interv,2016, 9(5): e003114.
(check this in PDF content)
7
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365: 883-91.
(check this in PDF content)
8
Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, doubleblind, phase II trial. Lancet,2009, 374: 29-38.
(check this in PDF content)
9
Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012, 366: 9-19.
(check this in PDF content)
10
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013, 381: 1107-15.
(check this in PDF content)
11
Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a doseadjusted oral vitamin K antagonist treatmentstrategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J, 2015, 169(4): 472-8.e5.
(check this in PDF content)
12
Popma CJ, Sheng S, Korjian S, et al. Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: results from the TRACER angiographic substudy. Circ Cardiovasc Interv,2016, 9(5): e003114.
(check this in PDF content)
13
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal doi:10.1093/eurheartj/ehw210
(check this in PDF content)
14
Stroke Prevention in Atrial Fibrillation Study Investigators. Final results. Circulation, 1991, 84(2): 527-539.
(check this in PDF content)